# TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435

> **NCT01022125** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 28 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** TMC435

## Key facts

- **NCT ID:** NCT01022125
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2010-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022125, "TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01022125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*